Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SHC vs STRL vs ICLR vs CRL vs MEDP

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SHC
Sotera Health Company

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.47B
5Y Perf.-42.1%
STRL
Sterling Infrastructure, Inc.

Engineering & Construction

IndustrialsNASDAQ • US
Market Cap$24.89B
5Y Perf.+4974.5%
ICLR
ICON Public Limited Company

Medical - Diagnostics & Research

HealthcareNASDAQ • IE
Market Cap$9.54B
5Y Perf.-35.9%
CRL
Charles River Laboratories International, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$8.98B
5Y Perf.-22.4%
MEDP
Medpace Holdings, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$12.24B
5Y Perf.+234.0%

SHC vs STRL vs ICLR vs CRL vs MEDP — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SHC logoSHC
STRL logoSTRL
ICLR logoICLR
CRL logoCRL
MEDP logoMEDP
IndustryMedical - Diagnostics & ResearchEngineering & ConstructionMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$4.47B$24.89B$9.54B$8.98B$12.24B
Revenue (TTM)$1.19B$2.88B$8.10B$4.03B$2.68B
Net Income (TTM)$118M$347M$599M$-185M$460M
Gross Margin55.3%22.8%26.9%24.9%29.1%
Operating Margin34.9%17.0%12.2%11.8%21.0%
Forward P/E16.3x59.1x10.5x16.4x25.2x
Total Debt$2.27B$350M$3.60B$3.07B$250M
Cash & Equiv.$346M$391M$539M$214M$497M

SHC vs STRL vs ICLR vs CRL vs MEDPLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SHC
STRL
ICLR
CRL
MEDP
StockNov 20May 26Return
Sotera Health Compa… (SHC)10057.9-42.1%
Sterling Infrastruc… (STRL)1005074.5+4974.5%
ICON Public Limited… (ICLR)10064.1-35.9%
Charles River Labor… (CRL)10077.6-22.4%
Medpace Holdings, I… (MEDP)100334.0+234.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: SHC vs STRL vs ICLR vs CRL vs MEDP

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MEDP leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Sterling Infrastructure, Inc. is the stronger pick specifically for recent price momentum and sentiment. ICLR also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SHC
Sotera Health Company
The Income Pick

SHC is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 2 yrs, beta 1.32
  • Lower volatility, beta 1.32, current ratio 2.46x
  • Beta 1.32, current ratio 2.46x
Best for: income & stability and sleep-well-at-night
STRL
Sterling Infrastructure, Inc.
The Long-Run Compounder

STRL is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 176.9% 10Y total return vs MEDP's 14.4%
  • +351.7% vs ICLR's -10.0%
Best for: long-term compounding
ICLR
ICON Public Limited Company
The Value Play

ICLR ranks third and is worth considering specifically for value.

  • Lower P/E (10.5x vs 16.4x)
Best for: value
CRL
Charles River Laboratories International, Inc.
The Healthcare Pick

Among these 5 stocks, CRL doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MEDP
Medpace Holdings, Inc.
The Growth Play

MEDP carries the broadest edge in this set and is the clearest fit for growth exposure and valuation efficiency.

  • Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
  • PEG 0.79 vs ICLR's 1.50
  • 20.0% revenue growth vs CRL's -0.9%
  • 17.2% margin vs CRL's -4.6%
Best for: growth exposure and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMEDP logoMEDP20.0% revenue growth vs CRL's -0.9%
ValueICLR logoICLRLower P/E (10.5x vs 16.4x)
Quality / MarginsMEDP logoMEDP17.2% margin vs CRL's -4.6%
Stability / SafetyMEDP logoMEDPBeta 1.26 vs STRL's 2.54
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)STRL logoSTRL+351.7% vs ICLR's -10.0%
Efficiency (ROA)MEDP logoMEDP24.8% ROA vs CRL's -2.5%, ROIC 154.9% vs 6.3%

SHC vs STRL vs ICLR vs CRL vs MEDP — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SHCSotera Health Company
FY 2025
Service
85.6%$996M
Product
14.4%$168M
STRLSterling Infrastructure, Inc.
FY 2025
E-Infrastructure Solutions Segment
58.9%$1.5B
Transportation Solutions Segment
25.7%$641M
Building Solutions Segment
15.4%$383M
ICLRICON Public Limited Company
FY 2012
Clinical Research
92.2%$1.0B
Central Laboratory
7.8%$87M
CRLCharles River Laboratories International, Inc.
FY 2025
Discovery and Safety Assessment
59.8%$2.4B
Research Models and Services
21.1%$846M
Manufacturing Support
19.1%$766M
MEDPMedpace Holdings, Inc.
FY 2025
Oncology
29.5%$748M
Metabolic
29.4%$745M
Other
16.1%$409M
Central Nervous System
10.1%$255M
Cardiology
9.5%$239M
Antiviral And Anti Infective
5.3%$135M

SHC vs STRL vs ICLR vs CRL vs MEDP — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSHCLAGGINGCRL

Income & Cash Flow (Last 12 Months)

SHC leads this category, winning 3 of 6 comparable metrics.

ICLR is the larger business by revenue, generating $8.1B annually — 6.8x SHC's $1.2B. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to CRL's -4.6%. On growth, STRL holds the edge at +91.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSHC logoSHCSotera Health Com…STRL logoSTRLSterling Infrastr…ICLR logoICLRICON Public Limit…CRL logoCRLCharles River Lab…MEDP logoMEDPMedpace Holdings,…
RevenueTrailing 12 months$1.2B$2.9B$8.1B$4.0B$2.7B
EBITDAEarnings before interest/tax$517M$575M$1.4B$757M$577M
Net IncomeAfter-tax profit$118M$347M$599M-$185M$460M
Free Cash FlowCash after capex$112M$440M$996M$391M$745M
Gross MarginGross profit ÷ Revenue+55.3%+22.8%+26.9%+24.9%+29.1%
Operating MarginEBIT ÷ Revenue+34.9%+17.0%+12.2%+11.8%+21.0%
Net MarginNet income ÷ Revenue+9.9%+12.0%+7.4%-4.6%+17.2%
FCF MarginFCF ÷ Revenue+9.4%+15.3%+12.3%+9.7%+27.8%
Rev. Growth (YoY)Latest quarter vs prior year+10.0%+91.6%+0.6%+1.2%+26.5%
EPS Growth (YoY)Latest quarter vs prior year+2.9%+141.4%-98.7%-160.0%+16.6%
SHC leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ICLR leads this category, winning 5 of 7 comparable metrics.

At 13.1x trailing earnings, ICLR trades at a 85% valuation discount to STRL's 86.5x P/E. Adjusting for growth (PEG ratio), MEDP offers better value at 0.88x vs STRL's 1.95x — a lower PEG means you pay less per unit of expected earnings growth.

MetricSHC logoSHCSotera Health Com…STRL logoSTRLSterling Infrastr…ICLR logoICLRICON Public Limit…CRL logoCRLCharles River Lab…MEDP logoMEDPMedpace Holdings,…
Market CapShares × price$4.5B$24.9B$9.5B$9.0B$12.2B
Enterprise ValueMkt cap + debt − cash$6.4B$24.9B$12.6B$11.8B$12.0B
Trailing P/EPrice ÷ TTM EPS58.04x86.50x13.12x-62.52x28.06x
Forward P/EPrice ÷ next-FY EPS est.16.26x59.12x10.53x16.42x25.24x
PEG RatioP/E ÷ EPS growth rate1.95x1.87x0.88x
EV / EBITDAEnterprise value multiple21.09x50.58x7.95x12.98x21.31x
Price / SalesMarket cap ÷ Revenue3.84x10.00x1.15x2.24x4.84x
Price / BookPrice ÷ Book value/share7.41x22.70x1.09x2.81x27.57x
Price / FCFMarket cap ÷ FCF29.95x68.64x8.53x17.31x17.96x
ICLR leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

MEDP leads this category, winning 6 of 9 comparable metrics.

MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-6 for CRL. STRL carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHC's 3.75x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs CRL's 4/9, reflecting strong financial health.

MetricSHC logoSHCSotera Health Com…STRL logoSTRLSterling Infrastr…ICLR logoICLRICON Public Limit…CRL logoCRLCharles River Lab…MEDP logoMEDPMedpace Holdings,…
ROE (TTM)Return on equity+20.6%+32.3%+6.3%-5.7%+120.9%
ROA (TTM)Return on assets+3.7%+13.7%+3.6%-2.5%+24.8%
ROICReturn on invested capital+11.8%+38.9%+6.5%+6.3%+154.9%
ROCEReturn on capital employed+13.3%+28.5%+7.8%+8.1%+65.7%
Piotroski ScoreFundamental quality 0–966746
Debt / EquityFinancial leverage3.75x0.32x0.38x0.95x0.55x
Net DebtTotal debt minus cash$1.9B-$41M$3.1B$2.9B-$247M
Cash & Equiv.Liquid assets$346M$391M$539M$214M$497M
Total DebtShort + long-term debt$2.3B$350M$3.6B$3.1B$250M
Interest CoverageEBIT ÷ Interest expense2.38x27.17x3.96x6.38x
MEDP leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

STRL leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in STRL five years ago would be worth $350,047 today (with dividends reinvested), compared to $5,311 for CRL. Over the past 12 months, STRL leads with a +351.7% total return vs ICLR's -10.0%. The 3-year compound annual growth rate (CAGR) favors STRL at 167.8% vs ICLR's -13.0% — a key indicator of consistent wealth creation.

MetricSHC logoSHCSotera Health Com…STRL logoSTRLSterling Infrastr…ICLR logoICLRICON Public Limit…CRL logoCRLCharles River Lab…MEDP logoMEDPMedpace Holdings,…
YTD ReturnYear-to-date-11.4%+154.2%-33.7%-10.1%-24.9%
1-Year ReturnPast 12 months+19.2%+351.7%-10.0%+32.8%+42.9%
3-Year ReturnCumulative with dividends+4.6%+1819.6%-34.1%-4.2%+104.6%
5-Year ReturnCumulative with dividends-36.3%+3400.5%-45.4%-46.9%+159.4%
10-Year ReturnCumulative with dividends-37.6%+17694.1%+91.0%+119.2%+1442.7%
CAGR (3Y)Annualised 3-year return+1.5%+167.8%-13.0%-1.4%+27.0%
STRL leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — STRL and MEDP each lead in 1 of 2 comparable metrics.

MEDP is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than STRL's 2.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. STRL currently trades 91.3% from its 52-week high vs ICLR's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSHC logoSHCSotera Health Com…STRL logoSTRLSterling Infrastr…ICLR logoICLRICON Public Limit…CRL logoCRLCharles River Lab…MEDP logoMEDPMedpace Holdings,…
Beta (5Y)Sensitivity to S&P 5001.32x2.54x1.60x1.52x1.26x
52-Week HighHighest price in past year$19.85$888.95$211.00$228.88$628.92
52-Week LowLowest price in past year$10.80$171.38$66.57$131.30$284.48
% of 52W HighCurrent price vs 52-week peak+78.9%+91.3%+59.2%+79.5%+68.2%
RSI (14)Momentum oscillator 0–10056.588.362.157.240.6
Avg Volume (50D)Average daily shares traded3.1M498K1.1M806K371K
Evenly matched — STRL and MEDP each lead in 1 of 2 comparable metrics.

Analyst Outlook

SHC leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SHC as "Buy", STRL as "Buy", ICLR as "Buy", CRL as "Buy", MEDP as "Hold". Consensus price targets imply 40.4% upside for SHC (target: $22) vs -39.8% for STRL (target: $488).

MetricSHC logoSHCSotera Health Com…STRL logoSTRLSterling Infrastr…ICLR logoICLRICON Public Limit…CRL logoCRLCharles River Lab…MEDP logoMEDPMedpace Holdings,…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$22.00$488.20$149.63$205.43$498.86
# AnalystsCovering analysts129303619
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises211
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.3%+5.2%+4.0%+7.5%
SHC leads this category, winning 1 of 1 comparable metric.
Key Takeaway

SHC leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). ICLR leads in 1 (Valuation Metrics). 1 tied.

Best OverallSotera Health Company (SHC)Leads 2 of 6 categories
Loading custom metrics...

SHC vs STRL vs ICLR vs CRL vs MEDP: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SHC or STRL or ICLR or CRL or MEDP a better buy right now?

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Sotera Health Company (SHC) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SHC or STRL or ICLR or CRL or MEDP?

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Sterling Infrastructure, Inc. at 86. 5x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 79x versus ICON Public Limited Company's 1. 50x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — SHC or STRL or ICLR or CRL or MEDP?

Over the past 5 years, Sterling Infrastructure, Inc.

(STRL) delivered a total return of +34. 0%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: STRL returned +176. 9% versus SHC's -37. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SHC or STRL or ICLR or CRL or MEDP?

By beta (market sensitivity over 5 years), Medpace Holdings, Inc.

(MEDP) is the lower-risk stock at 1. 26β versus Sterling Infrastructure, Inc. 's 2. 54β — meaning STRL is approximately 102% more volatile than MEDP relative to the S&P 500. On balance sheet safety, Sterling Infrastructure, Inc. (STRL) carries a lower debt/equity ratio of 32% versus 4% for Sotera Health Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — SHC or STRL or ICLR or CRL or MEDP?

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Sotera Health Company grew EPS 68. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SHC or STRL or ICLR or CRL or MEDP?

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHC leads at 33. 8% versus 12. 6% for CRL. At the gross margin level — before operating expenses — SHC leads at 55. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SHC or STRL or ICLR or CRL or MEDP more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 79x versus ICON Public Limited Company's 1. 50x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 5x forward P/E versus 59. 1x for Sterling Infrastructure, Inc. — 48. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SHC: 40. 4% to $22. 00.

08

Which pays a better dividend — SHC or STRL or ICLR or CRL or MEDP?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SHC or STRL or ICLR or CRL or MEDP better for a retirement portfolio?

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Sterling Infrastructure, Inc. (STRL) carries a higher beta of 2. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1443%, STRL: +176. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SHC and STRL and ICLR and CRL and MEDP?

These companies operate in different sectors (SHC (Healthcare) and STRL (Industrials) and ICLR (Healthcare) and CRL (Healthcare) and MEDP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SHC is a small-cap quality compounder stock; STRL is a mid-cap high-growth stock; ICLR is a small-cap deep-value stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SHC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

STRL

High-Growth Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 45%
  • Net Margin > 7%
Run This Screen
Stocks Like

ICLR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

CRL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Stocks Like

MEDP

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 10%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SHC and STRL and ICLR and CRL and MEDP on the metrics below

Revenue Growth>
%
(SHC: 10.0% · STRL: 91.6%)
Net Margin>
%
(SHC: 9.9% · STRL: 12.0%)
P/E Ratio<
x
(SHC: 58.0x · STRL: 86.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.